Continuous infusion of recombinant interleukin-2 with or without autologous lymphokine activated killer cells for the treatment of advanced renal cell carcinoma
- 31 May 1992
- journal article
- Published by Elsevier in European Journal Of Cancer
- Vol. 28 (6-7), 1038-1044
- https://doi.org/10.1016/0959-8049(92)90450-g
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer PatientsAnnals of Surgery, 1989
- Metastatic renal cell cancer treated with low-dose interleukin-2. A phase-II multicentre studyCancer Treatment Reviews, 1989
- Interleukin-2: Inception, Impact, and ImplicationsScience, 1988
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- The Biochemistry, Biology, and Role of Interleukin 2 in the Induction of Cytotoxic T Cell and Antibody‐Forming B Cell ResponsesImmunological Reviews, 1982
- Long term culture of tumour-specific cytotoxic T cellsNature, 1977
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958